 Part 2 is a double-masked design to assess the safetytolerability, pharmacokinetics and pharmacodynamics of a single IVT dose of LKA651 when co-administered with Lucentis. A total of up to 3 cohorts 8 subjects per cohort may be enrolled in Part 2. Each subject will participate in a screeningeligibility period up to 60 days, a treatment period combination therapy, single day, and an 84 day follow up period. A total of up to 11 visits will take place, all on an out-patient basis. For the LKA651 vs sham injections, the unmasked ophthalmologist is not permitted to do any of the assessments except for the injection and an inspection of the injection site immediately following. All other ocular assessments after randomization will be conducted by a second ophthalmologist masked to the type of injection active or sham. The Lucentis injection Part 2 is given open label to all patients following either the LKA651 or sham injection. 